Our Story

The hunt for a Non-Invasive Glucose Monitoring has taken place for over 60 years without any breakthrough by the industry. Several technologies have been tested from infrared light etc. with no success. Because of the enormous need for a reliable and affordable sensors by millions of diabetics, the hunt is ongoing.

2010- The idea was born

The idea was born to apply Newton´s Second law and Stokes law of attenuation to monitor the blood glucose level in diabetics as a function of density and changed viscosity.
Theoretical evaluation in cooperation with Swedish institutions by KTH (Royal Technological Institue) in Stockholm and Mid Sweden University in Sundsvall.
First patent application filed

2011 - Mecsense AS incorporated as a Norwegian corporation

2012 - Modelling of the principle

Modelling of the principle by Mid Sweden University and ShortLink AB in Karlstad, Sweden with the following conclusion “From the stipulated facts and study into the possibility of using the piezoelectric transducer as a part of non-invasive glucose monitoring method, establishes that the said approach is valid”

2013 - Principle tested with a prototype

Principle tested with a prototype in laboratory environment at Mid Sweden University and principle verified in February
Layout of the first sensor for tests on biological water with glucose designed by professor Oelmann at Mid Sweden University, Sundsvall, Sweden
First version of prototype created
Second patent application filed

2014 - First in-house human pilot tests conducted with positive results

Design of three stationary sensors with all electronics mounted on a circuit board.
The results was promising with a deviation of less than ± 15% which is the present required accuracy of glucose meters.

2015-17 - Further in-house pilot tests on humans

Research at Mid Sweden University, by public funding
Granted in total NOK 6 million in public funding during this period by The Research Council of Norway and Innovation Norway.
Extensive in-house tests on diabetic and non diabetics showing promising results.
In-vitro test on repeatability with promising results.

2018

Technical improvements
Extensive lab testing at Sharelab, Oslo Science Park
Two patents granted in USA
Universal Biotech Innovation Prize runner-up in the Medtech category
Winner of the Medtech Track at the Nordic Mentor Network for Entrepreneurship.

2019 - Preparing for a clinical pilot study

Established contact with OUS (Oslo University Hospital) and MD PhD Kari Anne Sveen who is an Endocrinologist and Diabetes expert. In a meeting at Oslo Science Park January 25th she confirmed that she was interested in supporting us with clinical trials.
Received approval from REC (Committees for Medical and Health Research Ethics Norwegian) to perform clinical pilot trial.
On-going In-vivo human testing and preparation for the clinical pilot trials at ShareLab in Oslo Science Park.
Optimizing algorithm for analyzing of data and finding optimal pulses per pulse train and number of plus trains each minute.

2020 - Planning for a clinical pilot study managed by OUH (Oslo University Hospital)

Received approval from Norwegian Medical Agency.

2021 - Clinical pilot study conducted with success

• Performed a clinical pilot study with diabetics type 1.

2022-2024 - Preparing for commercialization of the technology

Developed a proprietary algorithm that translates nanosecond-level signal data into accurate blood glucose measurements (mmol/L), enabling real-time, non-invasive glucose monitoring.
Preparing for funding of next steps towards a commercial product

2025 - New team in place ready to take MecSense to the next level

International business- and technology team in place
Stepping up our visibility